Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Nantes University Hospital
Masonic Cancer Center, University of Minnesota
Institute of Hematology and Blood Transfusion, Czech Republic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
University of Manitoba
Wake Forest University Health Sciences
Mayo Clinic
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University of Alabama at Birmingham
University of Miami
M.D. Anderson Cancer Center
PedAL BCU, LLC
Stanford University
University of Arizona
Massachusetts General Hospital
Ohio State University Comprehensive Cancer Center
Hackensack Meridian Health
Dana-Farber Cancer Institute
University of Rochester
Mayo Clinic
M.D. Anderson Cancer Center
University of Rochester
Medical College of Wisconsin
Massachusetts General Hospital
University of Southern California
City of Hope Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
University of Kansas Medical Center
Massachusetts General Hospital
Assistance Publique - Hôpitaux de Paris
Dana-Farber Cancer Institute
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Washington
Thomas Jefferson University
University of Virginia
Institut Paoli-Calmettes
Fred Hutchinson Cancer Center
Assistance Publique - Hôpitaux de Paris
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Manchester
M.D. Anderson Cancer Center